$Novo-Nordisk A/S(NVO)$ bought more shares to dca as it is very undervalued. Novo Nordisk is the world’s leading company in diabetes care, a market projected to continue growing due to rising global obesity rates and aging populations. The company holds a dominant market share in insulin and GLP-1 receptor agonists, a class of drugs that have revolutionized diabetes and obesity treatment. Ozempic (for type 2 diabetes) and Wegovy (for obesity) have seen surging demand, with prescriptions continuing to rise globally.
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Buy Open | 73.88 7 | -34.71% Holding |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links: